These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21865399)

  • 1. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
    Grommes C; Oxnard GR; Kris MG; Miller VA; Pao W; Holodny AI; Clarke JL; Lassman AB
    Neuro Oncol; 2011 Dec; 13(12):1364-9. PubMed ID: 21865399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
    Heon S; Yeap BY; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2010 Dec; 16(23):5873-82. PubMed ID: 21030498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
    Yu HA; Sima C; Feldman D; Liu LL; Vaitheesvaran B; Cross J; Rudin CM; Kris MG; Pao W; Michor F; Riely GJ
    Ann Oncol; 2017 Feb; 28(2):278-284. PubMed ID: 28073786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    Hong MH; Choi YJ; Ahn HK; Lim SM; Keam B; Kim DW; Kim TM; Youk J; Kim YJ; Hwang S; Kim S; Kim JW; Kim HR; Kang JH
    JAMA Oncol; 2024 Oct; 10(10):1342-1351. PubMed ID: 39145962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
    Togashi Y; Masago K; Masuda S; Mizuno T; Fukudo M; Ikemi Y; Sakamori Y; Nagai H; Kim YH; Katsura T; Mishima M
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):399-405. PubMed ID: 22806307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Togashi Y; Masago K; Fukudo M; Tsuchido Y; Okuda C; Kim YH; Ikemi Y; Sakamori Y; Mio T; Katsura T; Mishima M
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1089-92. PubMed ID: 21681573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
    Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
    Lo PC; Dahlberg SE; Nishino M; Johnson BE; Sequist LV; Jackman DM; Jänne PA; Oxnard GR
    Cancer; 2015 Aug; 121(15):2570-7. PubMed ID: 25876525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
    Welsh JW; Komaki R; Amini A; Munsell MF; Unger W; Allen PK; Chang JY; Wefel JS; McGovern SL; Garland LL; Chen SS; Holt J; Liao Z; Brown P; Sulman E; Heymach JV; Kim ES; Stea B
    J Clin Oncol; 2013 Mar; 31(7):895-902. PubMed ID: 23341526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
    Yamada K; Takayama K; Kawakami S; Saruwatari K; Morinaga R; Harada T; Aragane N; Nagata S; Kishimoto J; Nakanishi Y; Ichinose Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):629-35. PubMed ID: 23599349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
    Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
    J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
    Clarke JL; Pao W; Wu N; Miller VA; Lassman AB
    J Neurooncol; 2010 Sep; 99(2):283-6. PubMed ID: 20146086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
    Togashi Y; Masago K; Fukudo M; Terada T; Fujita S; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
    J Thorac Oncol; 2010 Jul; 5(7):950-5. PubMed ID: 20479691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.